165 related articles for article (PubMed ID: 3943107)
1. Steady-state nonlinear pharmacokinetics of 5-fluorouracil during hepatic arterial and intravenous infusions in cancer patients.
Wagner JG; Gyves JW; Stetson PL; Walker-Andrews SC; Wollner IS; Cochran MK; Ensminger WD
Cancer Res; 1986 Mar; 46(3):1499-506. PubMed ID: 3943107
[TBL] [Abstract][Full Text] [Related]
2. Regional pharmacokinetics of 5-bromo-2'-deoxyuridine and 5-fluorouracil in dogs: hepatic arterial versus portal venous infusions.
Kuan HY; Smith DE; Ensmiger WD; Knol JA; DeRemer SJ; Yang Z; Stetson PL
Cancer Res; 1996 Oct; 56(20):4724-7. PubMed ID: 8840990
[TBL] [Abstract][Full Text] [Related]
3. Portal levels and hepatic clearance of 5-fluorouracil after intraperitoneal administration in humans.
Speyer JL; Sugarbaker PH; Collins JM; Dedrick RL; Klecker RW; Myers CE
Cancer Res; 1981 May; 41(5):1916-22. PubMed ID: 7214359
[TBL] [Abstract][Full Text] [Related]
4. Clinical pharmacological studies of concurrent infusion of 5-fluorouracil and thymidine in treatment of colorectal carcinomas.
Au JL; Rustum YM; Ledesma EJ; Mittelman A; Creaven PJ
Cancer Res; 1982 Jul; 42(7):2930-7. PubMed ID: 6211226
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological evaluation of experimental isolated liver perfusion and hepatic artery infusion with 5-fluorouracil.
de Brauw LM; Marinelli A; van de Velde CJ; Hermans J; Tjaden UR; Erkelens C; de Bruijn EA
Cancer Res; 1991 Mar; 51(6):1694-700. PubMed ID: 1998960
[TBL] [Abstract][Full Text] [Related]
6. Nonlinear pharmacokinetics of thymidine, thymine, and fluorouracil and their kinetic interactions in normal dogs.
Covey JM; Straw JA
Cancer Res; 1983 Oct; 43(10):4587-95. PubMed ID: 6883317
[TBL] [Abstract][Full Text] [Related]
7. Dose and flow dependence of 5-fluorouracil elimination by the isolated perfused rat liver.
Warren BS; LaCreta FP; Kornhauser DM; Williams WM
Cancer Res; 1987 Oct; 47(20):5261-5. PubMed ID: 3652033
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of 5-fluorouracil following different routes of intrahepatic administration in the canine model.
Didolkar MS; Covell DG; Jackson AJ; Walker AP; Kalidindi SR
Cancer Res; 1984 Nov; 44(11):5105-9. PubMed ID: 6488170
[TBL] [Abstract][Full Text] [Related]
9. Nonlinear pharmacokinetics of cyclophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation.
Chen TL; Passos-Coelho JL; Noe DA; Kennedy MJ; Black KC; Colvin OM; Grochow LB
Cancer Res; 1995 Feb; 55(4):810-6. PubMed ID: 7850794
[TBL] [Abstract][Full Text] [Related]
10. Clinical pharmacology of hepatic arterial infusions of 5-bromo-2'-deoxyuridine.
Ensminger WD; Walker SC; Stetson PL; Wagner JG; Knol JA; Lawrence TS; Andrews JC
Cancer Res; 1994 Apr; 54(8):2121-4. PubMed ID: 8174116
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of intraarterial mitomycin C in humans.
Hu E; Howell SB
Cancer Res; 1983 Sep; 43(9):4474-7. PubMed ID: 6409404
[TBL] [Abstract][Full Text] [Related]
12. Effects of route of administration and blood flow on hepatic drug elimination.
Shand DG; Kornhauser DM; Wilkinson GR
J Pharmacol Exp Ther; 1975 Dec; 195(3):424-32. PubMed ID: 1195129
[TBL] [Abstract][Full Text] [Related]
13. [Evaluation of 5-fluorouracil concentration in peripheral blood and side effects in continuous hepatic arterial infusion chemotherapy for patients with unresectable liver cancer].
Fujii K; Nakashima K; Ohno T; Anai H
Gan To Kagaku Ryoho; 1997 Sep; 24(12):1835-7. PubMed ID: 9382545
[TBL] [Abstract][Full Text] [Related]
14. On the differential affinities of two anticancer analogues to their target.
Holl E; Zänker KS; Lange J; Siewert JR
Drugs Exp Clin Res; 1985; 11(2):133-9. PubMed ID: 2941256
[TBL] [Abstract][Full Text] [Related]
15. Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil.
Ho DH; Pazdur R; Covington W; Brown N; Huo YY; Lassere Y; Kuritani J
Clin Cancer Res; 1998 Sep; 4(9):2085-8. PubMed ID: 9748123
[TBL] [Abstract][Full Text] [Related]
16. Comparison of 5-fluorouracil pharmacokinetics in whole blood, plasma, and red blood cells in patients with colorectal cancer.
Wattanatorn W; McLeod HL; Macklon F; Reid M; Kendle KE; Cassidy J
Pharmacotherapy; 1997; 17(5):881-6. PubMed ID: 9324177
[TBL] [Abstract][Full Text] [Related]
17. Nonlinear pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide/aldophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation.
Chen TL; Kennedy MJ; Anderson LW; Kiraly SB; Black KC; Colvin OM; Grochow LB
Drug Metab Dispos; 1997 May; 25(5):544-51. PubMed ID: 9152592
[TBL] [Abstract][Full Text] [Related]
18. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile.
Heggie GD; Sommadossi JP; Cross DS; Huster WJ; Diasio RB
Cancer Res; 1987 Apr; 47(8):2203-6. PubMed ID: 3829006
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of 5-fluorouracil assessed with a sensitive mass spectrometric method in patients on a dose escalation schedule.
van Groeningen CJ; Pinedo HM; Heddes J; Kok RM; de Jong AP; Wattel E; Peters GJ; Lankelma J
Cancer Res; 1988 Dec; 48(23):6956-61. PubMed ID: 3180104
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of 5-fluorouracil (5-FUra) in patients with metastatic colorectal cancer receiving 5-FUra bolus plus continuous infusion with high dose folinic acid (LV5FU2).
Joulia JM; Pinguet F; Ychou M; Duffour J; Topart D; Grosse PY; Astre C; Bressolle F
Anticancer Res; 1997; 17(4A):2727-30. PubMed ID: 9252705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
